Back

Chitinase 3-like-1 is a Therapeutic Target That Mediates the Effects of Aging in COVID-19

Kamle, S.; Ma, B.; He, C. H.; Akosman, B.; Zhou, Y.; Lee, C.-M.; El-Deiry, W. S.; Huntington, K.; Liang, O.; Machan, J. T.; Kang, M.-J.; Shin, H. J.; Mizoguchi, E.; Lee, C. G.; Elias, J. A.

2021-01-06 immunology
10.1101/2021.01.05.425478 bioRxiv
Show abstract

COVID-19 is caused by the SARS-CoV-2 (SC2) virus and is more prevalent and severe in the elderly and patients with comorbid diseases (CM). Because chitinase 3-like-1 (CHI3L1) is induced during aging and CM, the relationships between CHI3L1 and SC2 were investigated. Here we demonstrate that CHI3L1 is a potent stimulator of the SC2 receptor ACE2 and viral spike protein priming proteases (SPP), that ACE2 and SPP are induced during aging and that anti-CHI3L1, kasugamycin and inhibitors of phosphorylation, abrogate these ACE2- and SPP-inductive events. Human studies also demonstrated that the levels of circulating CHI3L1 are increased in the elderly and patients with CM where they correlate with COVID-19 severity. These studies demonstrate that CHI3L1 is a potent stimulator of ACE2 and SPP; that this induction is a major mechanism contributing to the effects of aging during SC2 infection and that CHI3L1 coopts the CHI3L1 axis to augment SC2 infection. CHI3L1 plays a critical role in the pathogenesis of and is an attractive therapeutic target in COVID-19.

Published in JCI Insight (predicted rank #1) · training set

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.